FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
50 letters match. Newest first.
-
DrugsLovelace Biomedical Research Institute
Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.
Medium -
BiologicsStephen J. Fallon, Ph.D.
FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.
High risk -
DrugsMaria E. De La Torre Silva, M.D.
Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.
Medium -
DrugsPratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.
FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.
High risk -
DrugsJose M. Carpio, M.D.
FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.
Medium -
DrugsNaseem A. Jaffrani, M.D.
FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.
High risk -
DrugsMukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre
FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.
High risk -
DrugsVedic Lifesciences Pvt. Ltd.
FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.
Medium -
DrugsMark S. Dacey, M.D.
FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.
High risk -
DrugsProdrome Sciences USA, LLC
Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.
High risk -
DrugsPurushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital
FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.
High risk -
DrugsDevalingam Mahalingam, M.D., Ph.D.
FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.
High risk -
DrugsMaria A. Carballosa, M.D.
FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.
Medium -
DrugsVerdure Sciences, Inc.
FDA says Verdure Sciences ran a clinical trial of Maplifa without submitting a required IND.
High risk -
DrugsRalph A. DeFronzo, M.D.
FDA warns Dr. Ralph A. DeFronzo for enrolling ineligible subjects and failing to promptly report study changes to the IRB.
High risk -
DrugsMark J. Savant, M.D
FDA warns clinical investigator Mark J. Savant, M.D., over protocol dosing and eligibility failures and missing informed consent in a drug trial.
High risk -
DrugsPeter Michael, M.D.
FDA warns clinical investigator Peter Michael, M.D. that pediatric trial subjects received twice the protocol's maximum drug dose.
High risk -
BiologicsAmy Lightner, MD
FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.
High risk -
DevicesUnited Health Products, Inc.
FDA warns United Health Products over unapproved significant-risk study of CelluSTAT absorbable hemostat and trial oversight failures.
High risk -
DrugsNana Barseghian, M.D.
FDA warns clinical investigator Nana Barseghian for enrolling high-body-mass-index subjects in drug trials despite protocol exclusion.
High risk -
DrugsAmerico F. Padilla, M.D.
FDA warns clinical investigator Americo F. Padilla, M.D. over failing to obtain parental consent before enrolling pediatric subjects in drug trials.
High risk -
DrugsMehran Michael Bahrami, M.D.
FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.
High risk -
DrugsHan C. Phan, M.D.
FDA warns clinical investigator Dr. Han C. Phan over failure to follow a drug study’s protocol for required tests.
Medium -
DrugsRichard W. Foltin, Ph.D.
FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.
High risk -
BiologicsKonrad Rejdak, M.D., Ph.D.
FDA warns Dr. Konrad Rejdak over clinical trial data integrity failures in a CIDP immune globulin study.
Medium -
BiologicsMassachusetts Institute of Technology MIT
FDA says MIT's review board for human research failed to make sure consent forms and meeting records met federal rules.
Medium -
DrugsKevin R. Bender, M.D./DBC Research Corporation
Clinical investigator Kevin R. Bender failed to secure a controlled investigational drug, and 110 kits were stolen.
High risk -
DrugsBret R. Rutherford, M.D.
FDA warned Dr. Bret R. Rutherford for enrolling ineligible patients in two drug studies by skipping required antidepressant washout.
High risk -
DrugsNew York State Psychiatric Institute IRB
FDA warned New York State Psychiatric Institute's review board it failed to report serious research problems and reviewed drug studies without required nonscientific member.
High risk -
DrugsJeffrey W. Taub, M.D./Children's Hospital of Michigan
FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.
High risk -
DrugsAnish S. Shah, M.D./Siyan Clinical Research
FDA warned clinical investigator Dr. Anish Shah that he broke blinding rules in a depression drug study, calling the site's data into question.
Medium -
DrugsMaria W. Greenwald, M.D.
FDA warned Dr. Maria W. Greenwald over clinical trial violations involving investigational drugs, including ineligible subjects and inaccurate records.
High risk -
DrugsAntonio E. Blanco, M.D./Vista Health Research, LLC
FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.
High risk -
DrugsLuis Javier Pena-Hernandez, M.D., FCCP
FDA warns Dr. Pena-Hernandez over ineligible subject enrollment and lapsed IRB approval for investigational drugs.
High risk -
DrugsRandy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.
FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.
High risk -
DrugsMobeen Mazhar, M.D.
FDA warned clinical investigator Dr. Mobeen Mazhar for enrolling ineligible subjects, missing safety reports, and consenting a subject late in drug trials.
High risk -
DrugsRobert J. Hayashi, M.D./Washington University School of Medicine, Department of Pediatrics
FDA warned Dr. Robert J. Hayashi over protocol deviations in pediatric drug trials that exposed a child to unnecessary study drug and invasive procedures.
High risk -
DrugsMaggie Jeffries, M.D. / Avanti Anesthesiology, LLC
FDA warns Houston clinical investigator Dr. Maggie Jeffries for running drug trials without an IND and with informed-consent failures.
High risk -
DrugsLarkin Community Hospital Institutional Review Board
Larkin Community Hospital IRB cited for approving trials without required nonscientist member and incomplete records.
Medium -
Drugs"David M. Lubeck, M.D./Arbor Centers for EyeCare
FDA warned Dr. David Lubeck for running a combination-drug study without an IND and enrolling five subjects.
High risk -
BiologicsValley Biosystems
FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.
High risk -
DrugsDaniel Fred Goodman, M.D./Goodman Eye Center
FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.
High risk -
DrugsSmitha C. Reddy, M.D./ACRC Studies, LLC
FDA warns Dr. Smitha Reddy over clinical trial protocol violations, including wrong drug given and broken blinding.
High risk -
DrugsSabine S. Hazan, M.D.
FDA warned Dr. Sabine Hazan that she enrolled and gave investigational drugs to subjects while IRB (ethics board) approval had lapsed.
High risk -
DrugsVasyl Melnyk, M.D.
FDA warns Dr. Vasyl Melnyk that he lost required records for an investigational drug trial.
Medium -
DrugsLauren R. Klein, MD, M.S.
FDA cited Dr. Lauren R. Klein for running two emergency department drug studies without required investigational new drug applications.
High risk -
DrugsJon B. Cole, MD
FDA warns Dr. Jon B. Cole he ran two pre-hospital drug studies without required INDs, adding risks for pregnant women, children, and intoxicated patients.
High risk -
DrugsRAAS Nutritionals, LLC/Rare Antibody Antigen Supply, Inc.
FDA says RAAS Nutritionals ran human drug studies without required IND applications, despite claiming products were dietary supplements.
High risk -
DrugsKaleido Biosciences, Inc.
Kaleido Biosciences ran COVID-19 clinical trials of KB109 without required IND, FDA says.
High risk -
DrugsEvelyn Lopez-Brignoni, M.D.
FDA warns Dr. Evelyn Lopez-Brignoni over inadequate dosing in pediatric investigational drug trials.
High risk